HEMA Biologics is a privately held biopharmaceutical company exclusively focused on meeting the needs of patients living with the rarest bleeding disorders. We aspire to support patients living with these disorders, partner with the broader community that cares for them, and bring meaningful treatments and services to help better their daily lives. Our product development focus is on rare bleeding disorders. Our product development focus is for the treatment of hemophilia A or B with inhibitors. For people living with these disorders, every day brings challenges. Our primary goal is to advance the treatment and management of these conditions in the US to positively affect patients’ lives. HEMA Biologics takes pride in the heritage of LFB, the manufacturer of its products. LFB is a global leader in manufacturing safe, ultrapure plasma-based products as well as a pioneer in innovative recombinant technologies. We are excited to bring these products and technologies to North America. To learn more about our mission and values, and for all HEMA Biologics information, visit our site: http://www.hemabio.com/. You can also follow us on Facebook by searching “HEMA Biologics.”